The two companies will use ALT-B4 to develop a subcutaneous version of the antibody-drug conjugate (ADC) cancer treatment ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

Sales Focus Inc. (SFI), a leading provider of outsourced sales solutions, was awarded Best Global B2B Outsourced Sales Services Provider in 2024 by ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Carebook Technologies Inc. ("Carebook" or the "Company") (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, will release its financial results for the quarter ended ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...